PolyActiva Secures AUD $40 Million in Series C Funding to Advance PA5108 and PREZIA Drug Delivery Platform

PolyActiva 获得 4000 万澳元 C 轮融资，用于推进 PA5108 和 PREZIA 药物递送平台的发展

June 16, 2025

2025年6月16日

PolyActiva has raised AUD $40 million in a Series C financing round to further the clinical development of its lead product, PA5108, a biodegradable sustained-release ocular implant targeting intraocular pressure (IOP) reduction in glaucoma and ocular hypertension patients. The funding will also support the company’s proprietary PREZIA platform and its broader therapeutic pipeline..

PolyActiva 在 C 轮融资中筹集了 4000 万澳元，以进一步推动其主导产品 PA5108 的临床开发。PA5108 是一种可生物降解的缓释眼部植入物，旨在降低青光眼和高眼压患者的眼内压 (IOP)。这笔资金还将支持该公司的专有 PREZIA 平台及其更广泛的治疗产品管线。

Clinical Development Progress of PA5108 for Glaucoma Management

PA5108用于青光眼管理的临床开发进展

PA5108 is designed to deliver latanoprost, a first-line treatment for glaucoma, via a biodegradable ocular implant. Uniquely, the implant is engineered to fully degrade after drug release, allowing for repeat dosing without requiring surgical removal.

PA5108旨在通过一种可生物降解的眼部植入物递送拉坦前列素，这是治疗青光眼的一线药物。该植入物的独特之处在于其设计为在药物释放后完全降解，从而允许重复给药而无需手术移除。

The company’s phase 2 clinical trial, completed in late 2024, met its primary efficacy and safety endpoints, demonstrating significant IOP reduction over 26 weeks. A second phase 2 study confirmed the feasibility of repeat dosing after six months of therapy.

该公司于 2024 年底完成的 2 期临床试验达到了其主要有效性和安全性终点，显示在 26 周内眼压显著降低。第二项 2 期研究证实了在六个月治疗后重复给药的可行性。

PolyActiva is set to initiate a phase 2b study in Q2 2025 at U.S. clinical sites, assessing optimal dose, safety, and efficacy. Preparations are also underway for a pivotal phase 3 registration trial.

PolyActiva计划于2025年第二季度在美国的临床试验点启动一项二期b阶段研究，评估最佳剂量、安全性和有效性。同时，关键的三期注册试验的准备工作也在进行中。

PREZIA Platform Offers Customizable Approach to Ocular Drug Delivery

PREZIA平台提供可定制的眼部药物递送方法

The PREZIA drug delivery platform differentiates itself by using covalent bonding to attach therapeutics to a polymer backbone, rather than relying on passive diffusion. This approach enables:

PREZIA药物递送平台通过使用共价键将治疗药物连接到聚合物骨架上，而不是依赖被动扩散，从而实现差异化。这种方法能够：

• Customizable release durations ranging from one week to 12 months

• 可定制的发布期限，从一周到12个月不等

• Consistent and predictable drug delivery

• 一致且可预测的药物递送

• Compatibility with both small molecules and biologics

• 兼容小分子和生物制品

“This funding marks a pivotal step forward in our efforts to bring our innovative technology to glaucoma patients who struggle with daily medication adherence,” said Vanessa Waddell, CEO of PolyActiva. “Our PREZIA platform represents a breakthrough in precision drug delivery, with the goal of offering a customizable, safe, and effective alternative to traditional therapies.”.

“这笔资金标志着我们在为那些每日用药依从性差的青光眼患者提供创新技术方面迈出了关键一步，”PolyActiva首席执行官瓦妮莎·沃德尔表示。“我们的PREZIA平台代表了精准药物递送的突破，目标是提供一种可定制、安全且有效的传统疗法替代方案。”

Strategic Investment and Industry Support

战略投资与产业支持

The National Reconstruction Fund Corporation (NRFC) contributed AUD $27 million to the Series C round, alongside longstanding investor Brandon Capital.

国家重建基金公司（NRFC）与长期投资者布兰登资本（Brandon Capital）共同为C轮融资贡献了2700万澳元。

“PolyActiva’s breakthrough PREZIA technology represents more than advancing the treatment of glaucoma; it could redefine the standard of care for ocular drug delivery,” commented Chris Nave, PhD, co-founder and managing partner at Brandon Capital and chair of PolyActiva.

Waddell concluded by emphasizing the broader mission:

韦德尔在总结时强调了更广泛的使命：

“PolyActiva is on a mission to reduce glaucoma-related vision loss globally. This investment ensures we can complete our Phase 2b trial and prepare for a Phase 3 registration trial—bringing us closer to delivering a potential new therapy for glaucoma.”

“PolyActiva 致力于减少全球因青光眼导致的视力丧失。这项投资确保我们能够完成 2b 期试验，并为 3 期注册试验做好准备——让我们更接近为青光眼提供一种潜在的新疗法。”